Zinc Lozenges for the Common Cold: Dissecting the Meta-Analyses and Dose-Response Data
Last reviewed: 2026年3月21日7:02
Zinc lozenges represent one of the most studied and debated interventions for the common cold, with a research history spanning over four decades since the first randomized controlled trial by Eby and colleagues in 1984 reported a dramatic reduction in cold duration. The proposed mechanism centers on the hypothesis that free ionic zinc (Zn²⁺) released in the oropharynx can inhibit rhinovirus replication by interfering with viral capsid proteins, blocking the virus's ability to dock with ICAM-1 receptors on respiratory epithelial cells, and potentially modulating local immune responses including interferon production. However, the clinical trial literature has produced notably inconsistent results, and understanding why requires a careful examination of the formulation chemistry, dosing protocols, and study designs that distinguish positive trials from negative ones.
The critical variable that explains much of the inconsistency in zinc lozenge trials is the availability of free ionic zinc in the lozenge formulation. Zinc acetate lozenges release nearly 100% of their zinc as free Zn²⁺ ions, while zinc gluconate lozenges release a lower but still meaningful proportion. In contrast, many commercial lozenges contain additives such as citric acid, tartaric acid, sorbitol, or mannitol that chelate zinc ions, effectively reducing the concentration of free Zn²⁺ available to interact with viral particles in the throat. A systematic analysis by Hemilä demonstrated that trials using lozenges with high levels of free ionic zinc consistently showed positive results, while trials using formulations with low ionic zinc availability tended to show no benefit. This formulation-dependent effect has been a major source of confusion in meta-analyses that pool all zinc lozenge trials together without accounting for the chemistry of the specific products used.
When the analysis is restricted to trials using lozenges that deliver adequate doses of ionic zinc, the evidence becomes considerably more compelling. A 2017 meta-analysis by Hemilä and Chalker, published in the British Journal of Clinical Pharmacology, found that zinc acetate lozenges providing 80-92 mg of elemental zinc per day reduced cold duration by an average of 33%, while zinc gluconate lozenges at similar total doses reduced duration by approximately 28%. The dose-response relationship appears to plateau at around 75-80 mg of elemental zinc per day from lozenges, with no additional benefit observed at higher doses. Timing is also critical — the evidence strongly suggests that zinc lozenges should be initiated within 24 hours of symptom onset, with lozenges dissolved slowly every two to three hours during waking hours. Pelargonium sidoides, another well-studied cold remedy, has shown complementary benefits in meta-analyses and may work through different mechanisms, making it a potential companion to zinc in a multi-target approach to cold symptom management.
Despite the promising evidence, several important caveats deserve attention. Most zinc lozenge trials have been relatively small, typically enrolling 50-100 participants, and blinding is inherently challenging because zinc lozenges have a distinctive metallic taste that participants may recognize. Gastrointestinal side effects including nausea have been reported in approximately 5-10% of participants taking zinc lozenges, and prolonged daily use beyond two weeks may impair copper absorption and disrupt copper-zinc homeostasis. Zinc nasal sprays should be avoided entirely, as they have been associated with anosmia — permanent loss of smell — and the FDA issued a safety warning about intranasal zinc products in 2009. For consumers seeking to use zinc lozenges for cold support, the evidence suggests choosing zinc acetate or zinc gluconate lozenges without citric acid, starting within the first day of symptoms, and limiting use to one to two weeks at most.
The critical variable that explains much of the inconsistency in zinc lozenge trials is the availability of free ionic zinc in the lozenge formulation. Zinc acetate lozenges release nearly 100% of their zinc as free Zn²⁺ ions, while zinc gluconate lozenges release a lower but still meaningful proportion. In contrast, many commercial lozenges contain additives such as citric acid, tartaric acid, sorbitol, or mannitol that chelate zinc ions, effectively reducing the concentration of free Zn²⁺ available to interact with viral particles in the throat. A systematic analysis by Hemilä demonstrated that trials using lozenges with high levels of free ionic zinc consistently showed positive results, while trials using formulations with low ionic zinc availability tended to show no benefit. This formulation-dependent effect has been a major source of confusion in meta-analyses that pool all zinc lozenge trials together without accounting for the chemistry of the specific products used.
When the analysis is restricted to trials using lozenges that deliver adequate doses of ionic zinc, the evidence becomes considerably more compelling. A 2017 meta-analysis by Hemilä and Chalker, published in the British Journal of Clinical Pharmacology, found that zinc acetate lozenges providing 80-92 mg of elemental zinc per day reduced cold duration by an average of 33%, while zinc gluconate lozenges at similar total doses reduced duration by approximately 28%. The dose-response relationship appears to plateau at around 75-80 mg of elemental zinc per day from lozenges, with no additional benefit observed at higher doses. Timing is also critical — the evidence strongly suggests that zinc lozenges should be initiated within 24 hours of symptom onset, with lozenges dissolved slowly every two to three hours during waking hours. Pelargonium sidoides, another well-studied cold remedy, has shown complementary benefits in meta-analyses and may work through different mechanisms, making it a potential companion to zinc in a multi-target approach to cold symptom management.
Despite the promising evidence, several important caveats deserve attention. Most zinc lozenge trials have been relatively small, typically enrolling 50-100 participants, and blinding is inherently challenging because zinc lozenges have a distinctive metallic taste that participants may recognize. Gastrointestinal side effects including nausea have been reported in approximately 5-10% of participants taking zinc lozenges, and prolonged daily use beyond two weeks may impair copper absorption and disrupt copper-zinc homeostasis. Zinc nasal sprays should be avoided entirely, as they have been associated with anosmia — permanent loss of smell — and the FDA issued a safety warning about intranasal zinc products in 2009. For consumers seeking to use zinc lozenges for cold support, the evidence suggests choosing zinc acetate or zinc gluconate lozenges without citric acid, starting within the first day of symptoms, and limiting use to one to two weeks at most.